Abstract Alzheimer's disease (AD), the most common form of dementia, is preceded by years
of silent pathological change. Our objective was to examine the associations between …

Introduction Plasma biomarkers—cost effective, non‐invasive indicators of Alzheimer's
disease (AD) and related disorders (ADRD)—have largely been studied in clinical research …

Background Plasma p217+ tau has shown high concordance with cerebrospinal fluid (CSF)
and positron emission tomography (PET) measures of amyloid-β (Aβ) and tau in Alzheimer's …

Growing evidence supports the use of plasma levels of tau phosphorylated at threonine 181,
amyloid-β, neurofilament light and glial fibrillary acidic protein as promising biomarkers for …

Background: Plasma-based biomarkers would be potential biomarkers for early diagnosis of
Alzheimer's disease (AD) because they are more available and cost-effective than …

INTRODUCTION Detection of Alzheimer's disease (AD) pathophysiology among individuals
with mild cognitive changes and those experiencing subjective cognitive decline (SCD) …

Alzheimer's disease is the leading cause of dementia worldwide and is characterized by a
long preclinical phase in which amyloid-β and tau accumulate in the absence of cognitive …

Abstract Introduction Blood‐based Alzheimer's disease (AD) biomarkers provide
opportunities for community studies and across ethnic groups. We investigated blood …

Introduction Objectively‐defined subtle cognitive decline (Obj‐SCD) and plasma
phosphorylated‐tau181 (p‐tau181) are promising early Alzheimer's disease (AD) markers …

INTRODUCTION Blood biomarkers showed values for predicting future cognitive
impairment. Evidence from the community‐based cohort was limited only in high‐income …